6684-27-1

Basic information

• Product Name: 2,4-dichloro-6-isopropoxy-1,3,5-triazine
• Synonyms: 2,4-dichloro-6-isopropoxy-1,3,5-triazine
• CAS NO: 6684-27-1
• Molecular Formula: C₆H₇Cl₂N₃O
• Molecular Weight: 208.04528
• EINECS: 229-728-9
• Mol File: 6684-27-1.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 339.1°C at 760 mmHg
• Flash Point: 158.9°C
• Appearance: /
• Density: 1.383g/cm³
• Vapor Pressure: 0.000184mmHg at 25°C
• Refractive Index: 1.526
• CAS DataBase Reference: 2,4-dichloro-6-isopropoxy-1,3,5-triazine(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-dichloro-6-isopropoxy-1,3,5-triazine(6684-27-1)
• EPA Substance Registry System: 2,4-dichloro-6-isopropoxy-1,3,5-triazine(6684-27-1)

Safety Data

• Hazardous Substances Data: 6684-27-1(Hazardous Substances Data)

Usage

Synthesis Reference(s)

Synthetic Communications, 24, p. 2153, 1994 DOI: 10.1080/00397919408010229

InChI:InChI=1/C6H7Cl2N3O/c1-3(2)12-6-10-4(7)9-5(8)11-6/h3H,1-2H3

Upstream product

• 108-77-0 1,3,5-trichloro-2,4,6-triazine 
• 67-63-0 isopropyl alcohol 

Downstream Products

• 1207841-91-5 2-chloro-4-(2-chlorophenyl)-6-isopropoxy-1,3,5-triazine 
• 1207841-87-9 2,4-bis(2-chlorophenyl)-6-isopropoxy-1,3,5-triazine 

Relevant articles and documents

Design, Synthesis and Biological Evaluation of Novel Nonsteroidal Progesterone Receptor Antagonists Based on Phenylamino-1,3,5-triazine Scaffold

We report here the development of phenylamino-1,3,5-triazine derivatives as novel nonsteroidal progesterone receptor (PR) antagonists. PR plays key roles in various physiological systems, including the female reproductive system, and PR antagonists are promising candidates for clinical treatment of multiple diseases. By using the phenylamino-1,3,5-triazine scaffold as a template structure, we designed and synthesized a series of 4-cyanophenylamino-1,3,5-triazine derivatives. The synthesized compounds exhibited PR antagonistic activity, and among them, compound 12n was the most potent (IC50=0.30μM); it also showed significant binding affinity to the PR ligand-binding domain. Docking simulation supported the design rationale of the compounds. Our results suggest that the phenylamino-1,3,5-triazine scaffold is a versatile template for development of nonsteroidal PR antagonists and that the developed compounds are promising lead compounds for further structural development of nonsteroidal PR antagonists.

Antiviral activities of some new 2,4,6-trisubstituted 1,3,5-triazines having alkoxy and/or alkylamino groups

We report the preparation of C3-and CS-symmetrical 2,4,6-trisubstituted 1,3,5-triazine derivatives having alkoxy and/or alkylamino groups and results of biological evaluation of their anti-herpes simplex virus type 1 (anti-HSV-1) activity and cytotoxic activity against Vero cells. New targeted symmetrical molecules were obtained by using a method starting with 2,4,6-trichloro-1,3,5-triazine (1). Among the synthesized compounds, CS-symmetrical tri-aliphatic alkylamino-substituted compound 6s showed high anti-HSV-1 activity (EC50 = 5.4 μM) and low cytotoxicity (CC50 > 200 μM). The results of an SAR study suggested that the presence of two hydrogen bond donor protons of sec-amine functionality in the molecule is an important structural factor for expression of potential anti-HSV-1 activities.

NOVEL ORALLY BIOAVAILABLE BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF USING SAME

The present invention includes compositions that are useful in the prevention and/or treatment of breathing control diseases or disorders in a subject in need thereof. The present invention also includes a method of preventing and/or treating a respiratory disease or disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a composition of the invention. The present invention further includes a method of preventing destabilization or stabilizing breathing rhythm in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a composition of the invention.